{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:10:56Z","timestamp":1792714256616,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40265-018-0967-6","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T12:56:44Z","timestamp":1534510604000},"page":"1377-1382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Tecovirimat: First Global Approval"],"prefix":"10.1007","volume":"78","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"967_CR1","unstructured":"US FDA. FDA approves the first drug with an indication for treatment of smallpox; 2018. http:\/\/www.fda.gov\/. Accessed 16 July 2018."},{"issue":"5","key":"967_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/fvl.11.27","volume":"6","author":"DW Grosenbach","year":"2011","unstructured":"Grosenbach DW, Jordan R, Hruby DE. Development of the small-molecule antiviral ST-246R as a smallpox therapeutic. Future Virol. 2011;6(5):653\u201371.","journal-title":"Future Virol"},{"issue":"11","key":"967_CR3","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.3390\/v2112409","volume":"2","author":"R Jordan","year":"2010","unstructured":"Jordan R, Leeds JM, Tyavanagimatt S, et al. Development of ST-246R for treatment of poxvirus infections. Viruses. 2010;2(11):2409\u201335.","journal-title":"Viruses"},{"key":"967_CR4","unstructured":"SIGA Technologies Inc. TPOXX (tecovirimat) capsules for oral use: US prescribing information; 2018. http:\/\/www.fda.gov\/. Accessed 26 July 2018."},{"issue":"1","key":"967_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa1705688","volume":"379","author":"DW Grosenbach","year":"2018","unstructured":"Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44\u201353.","journal-title":"N Engl J Med"},{"key":"967_CR6","unstructured":"SIGA Technologies Inc. U.S. Food and Drug Administration approves SIGA Technologies\u2019 TPOXX\u00ae (tecovirimat) for the treatment of smallpox [media release]. 13 July 2018. http:\/\/www.siga.com\/."},{"issue":"20","key":"967_CR7","doi-asserted-by":"publisher","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","volume":"79","author":"G Yang","year":"2005","unstructured":"Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol. 2005;79(20):13139\u201349.","journal-title":"J Virol"},{"issue":"3","key":"967_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1128\/AAC.00959-12","volume":"57","author":"JM Leeds","year":"2013","unstructured":"Leeds JM, Fenneteau F, Gosselin NH, et al. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Antimicrob Agents Chemother. 2013;57(3):1136\u201343.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"967_CR9","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1128\/AAC.00904-12","volume":"56","author":"J Chinsangaram","year":"2012","unstructured":"Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother. 2012;56(9):4900\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"967_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1128\/AAC.01303-07","volume":"52","author":"R Jordan","year":"2008","unstructured":"Jordan R, Tien D, Bolken TC, et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother. 2008;52(5):1721\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"967_CR11","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1128\/AAC.06090-11","volume":"56","author":"J Chinsangaram","year":"2012","unstructured":"Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, et al. Pharmacokinetic comparison of a single oral dose of polymorph form I versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers. Antimicrob Agents Chemother. 2012;56(7):3582\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"967_CR12","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1128\/AAC.01689-09","volume":"54","author":"R Jordan","year":"2010","unstructured":"Jordan R, Chinsangaram J, Bolken TC, et al. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother. 2010;54(6):2560\u20136.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-018-0967-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0967-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0967-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:01:20Z","timestamp":1684861280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-018-0967-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":12,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0967-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"17 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sheridan Hoy is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}